Format

Send to

Choose Destination
Expert Opin Ther Pat. 2012 Dec;22(12):1427-42. doi: 10.1517/13543776.2012.729579. Epub 2012 Oct 3.

DNA methyltransferase inhibitors in cancer: a chemical and therapeutic patent overview and selected clinical studies.

Author information

1
USR 3388 Epigenetic Targeting of Cancer, CNRS-Pierre Fabre, CRDPF, BP 13562, 3 avenue Hubert Curien, 31 035 Toulouse CEDEX 01, France.

Abstract

INTRODUCTION:

DNA methylation is an epigenetic modification that modulates gene expression without altering the DNA base sequence. It plays a crucial role in cancer by silencing tumor suppressor genes (TSG). The DNA methyltransferases (DNMT) are the enzymes that catalyze DNA methylation and they are interesting therapeutical targets since DNA methylation is reversible such that an aberrant hypermethylation of DNA can be reverted by inhibition of DNMTs. Today, two drugs are on the market for the treatment of myelodysplastic syndrome, azacitidine and decitabine.

AREAS COVERED:

Here, we present a review of the patents describing the chemistry and biological activities of novel DNMT inhibitors and discuss select clinical studies.

EXPERT OPINION:

DNMT inhibitors have shown efficacy in clinics. However, highly efficient and specific DNMT inhibitors have not yet been identified. Improving methods will certainly lead to the prediction of novel directly binding inhibitors in the future.

PMID:
23033952
DOI:
10.1517/13543776.2012.729579
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center